G. Akabani et al., Dosimetry and dose-response relationships in newly diagnosed patients withmalignant gliomas treated with iodine-131-labeled anti-tenascin monoclonalantibody 81C6 therapy, INT J RAD O, 46(4), 2000, pp. 947-958
Citations number
34
Categorie Soggetti
Radiology ,Nuclear Medicine & Imaging","Onconogenesis & Cancer Research
Journal title
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS
Purpose: The objective of this study was to perform the dosimetry and evalu
ate the dose-response relationships in newly diagnosed patients with malign
ant brain tumors treated by direct injections of I-131-labeled 81C6 monoclo
nal antibody (MAb) into surgically created resection cavities (SCRCs).
Methods and Materials: Absorbed doses to the 2-cm-thick shell as measured f
rom the margins of the resection cavity interface were estimated for 42 pat
ients with primary brain tumors. MR images were used to assess the enhanced
-rim volume as a function of time after radiolabeled MAb therapy. Biopsy sa
mples were obtained from 15 patients and 1 autopsy.
Results: The average absorbed dose [range] to the 2-cm shell region was 32
[3-59] Gy. For the endpoint of minimal time to MR contrast enhancement, the
optimal absorbed dose and initial dose-rate were 43 +/- 16 Gy and 0.41 +/-
0.10 Gy/h, respectively. There was a correlation between the absorbed dose
and dose rate to the shell region and biopsy outcome (tumor recurrence, ra
dionecrosis, and tumor recurrence and/or radionecrosis). In this Phase I st
udy, the maximum tolerated dose (MTD) was 120 mCi. At this MTD, the estimat
ed average absorbed dose and initial dose rate to the 2-cm shell mere 41 [9
-89] Gy and 0.51 [0.24-1.13] Gy/h, respectively. These values are in agreem
ent with the optimal values based on the time to MR lesion rim enhancement.
Conclusions: The average absorbed dose to the 2-cm shell region varied cons
iderably and mainly depended on cavity volume. In future clinical trials, t
he administered activity of I-131-labeled 81C6 MAb may be adjusted based on
cavity volume in order to deliver the optimal absorbed dose of 43 Gy rathe
r than giving a fixed administered activity. (C) 2000 Elsevier Science Inc.